NuCana plc

Healthcare · Biotechnology · United Kingdom

Last price 1.04 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.48M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study...